Mammalian cell culture perfusion patents: who holds the claims and where the field is still open
25.5% concentration at the top. The five leading assignees hold 560 of 2,197 records in scope, but the remaining ranked leaders thin out fast — a long tail dominates by count of entrants. Filings rose to a peak of 83 in 2020, then eased — the last complete year-over-year comparison available shows 2021's 36 filings dropping to 25 by 2024, a 31% decline. Treat 2025 and 2026 as undercounted rather than as continued decline.
- 1AMGEN INC11.9%
- 2MERCK PATENT GMBH4.0%
- 3TAKEDA PHARMA CO LTD3.3%
- 4ARES TRADING SA3.3%
- 5BAXALTA GMBH3.0%
See the full mammalian cell culture perfusion culture analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
How concentrated is the mammalian cell culture perfusion patent field?
It is moderately concentrated at the very top and long-tailed after that. The five leading assignees hold 560 of 2,197 records in scope, or 25.5%, and the top ten hold 36.4% combined. Beyond the leader, which sits at 262 records, the drop to fifth place (66) and tenth place (41) is steep, meaning the ranked leaders past the top few file in much smaller, more comparable numbers, and the remaining majority of the field is spread across a long tail of smaller filers.
Why did filings appear to drop after 2020?
Publication lags filing by roughly 18 months, so any patent filed in 2025 or 2026 typically has not published yet and will not show up in a count taken today. The dataset's peak year is 2020 at 83 filings, and the last year-over-year comparison that can be treated as complete runs from 2021 (36) to 2024 (25), a 31% decline. Figures for 2025 and 2026 are still filling in and should not be read as evidence the technology is falling out of favor.
Which technology areas are under-claimed in perfusion cell culture?
The apparatus and monitoring layer looks comparatively open relative to the underlying biology. C12N, covering microorganisms and genetic engineering, appears in 84.3% of the 2,197 records, while C12M, covering bioreactors and enzyme apparatus, appears in only 32.0%. That gap suggests specific sub-areas such as bleed-rate control algorithms, single-use perfusion sensors and real-time residence-time monitoring carry comparatively less claim density than the expression and cell-line biology around them.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Mammalian Cell Culture Perfusion Culture covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.